Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Travere Therapeutics, Inc. (TVTX) had Revenue of $164.86M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$164.86M
Net Income	$25.71M
Cost of Goods Sold	$1.58M
Gross Profit	$163.27M
Operating Expenses	$139.93M
Operating Income	$24.93M
Non-Operating Income/Expense	$0.78M
Pre-Tax Income	$25.71M
Normalized Pre-Tax Income	$25.71M
Income after Taxes	$25.71M
Income from Continuous Operations	$25.71M
Consolidated Net Income/Loss	$25.71M
Normalized Income after Taxes	$25.71M
EBIT	$24.93M
EBITDA	$40.72M
Weighted-Average Shares Outstanding (Basic)	89.23M
Weighted-Average Shares Outstanding (Diluted)	102.62M
Earnings per Share (EPS) (Basic)	$0.29
Earnings per Share (EPS) (Diluted)	$0.28
Balance Sheet Financials
Current Assets	$371.11M
Property, Plant, and Equipment	$4.32M
Long-Term Assets	$167.47M
Total Assets	$538.58M
Current Liabilities	$135.07M
Long-Term Debt	$311.37M
Long-Term Liabilities	$329.94M
Total Liabilities	$465.02M
Common Equity	$73.56M
Tangible Shareholders Equity	$-35.87M
Shareholders Equity	$73.56M
Common Shares Outstanding	89.46M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-22.89M
Cash Flow from Investing Activities	$132.73M
Cash Flow from Financial Activities	$-60.15M
Beginning Cash	$58.53M
End Cash	$110.93M
Increase/Decrease in Cash	$52.40M
Stock-Based Compensation	$33.40M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.75
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.81
Debt to Equity Ratio	4.23
Gross Margin	99.04%
Operating Margin	15.12%
EBIT Margin	15.12%
EBITDA Margin	--
Pre-Tax Profit Margin	15.60%
Profit Margin	15.59%
Free Cash Flow	$-23.27M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.31
Inventory Turnover	0.29
Receiveable Turnover	1.99
Days Sales in Receivables	45.30
Return on Equity	34.94%
Return on Tangible Equity	-71.66%
Return on Assets	4.77%
Return on Investments	6.68%
Book Value Per Share	$0.82
Free Cash Flow per Share	$-0.23
Operating Cash Flow per Share	$-0.22

Data from Zacks Investment Research, Inc.